TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 21206277

Group type: EXPERIMENTAL
Intervention: Sub-Tenon lidocaine injection (2% lidocaine)
Number of subjects: 260

Group type: COMPARATOR
Intervention: Isotonic saline injection (1 ml)
Number of subjects: 260

Group type: COMPARATOR
Intervention: Sevoflurane anaesthesia
Number of subjects: 260

Group type: EXPERIMENTAL
Intervention: Propofol-remifentanil anaesthesia
Number of subjects: 260
Study: 18502614

Group type: EXPERIMENTAL
Intervention: Hyperhomocysteinemic patients
Number of subjects: 87

Group type: COMPARATOR
Intervention: Epileptic patients with normal t-Hcy levels
Number of subjects: 87

Group type: COMPARATOR
Intervention: Healthy subjects with normal t-Hcy levels
Number of subjects: 87
Study: 16610158

Group type: EXPERIMENTAL
Intervention: HIV seropositives (HIV +)
Number of subjects: 246
Study: 12970893

Group type: EXPERIMENTAL
Intervention: UCBT
Number of subjects: 153

Group type: EXPERIMENTAL
Intervention: UCBT+PE
Number of subjects: 153

Group type: COMPARATOR
Intervention: Adult plasma (control)
Number of subjects: 153

Group type: EXPERIMENTAL
Intervention: Plasma exchange (PE)
Number of subjects: 153

Group type: EXPERIMENTAL
Intervention: Neonate cord blood
Number of subjects: 153

Group type: EXPERIMENTAL
Intervention: Normal saline
Number of subjects: 153
Study: 11788013

Group type: EXPERIMENTAL
Intervention: Pergolide therapy
Number of subjects: 22
Study: 9459393

Group type: EXPERIMENTAL
Intervention: 25 microg p24-VLP in Alum adjuvant
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: 100 microg p24-VLP in Alum adjuvant
Number of subjects: 15

Group type: COMPARATOR
Intervention: Aluminium hydroxide placebo
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: All groups
Number of subjects: 15
Study: 16353581

Group type: EXPERIMENTAL
Intervention: Clomipramine (CMI) 12.5 mg
Number of subjects: 19
Study: 3356082

Group type: EXPERIMENTAL
Intervention: Ferrous sulfate (325 mg) with methyldopa (500 mg)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Ferrous gluconate (600 mg) with methyldopa (500 mg)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Ferrous sulfate (325 mg) in hypertensive subjects
Number of subjects: 12
Study: 29534131

Group type: EXPERIMENTAL
Intervention: Trephine core procedure
Number of subjects: 0

Group type: COMPARATOR
Intervention: Bone-added osteotome sinus floor elevation technique
Number of subjects: 0
Study: 27752170

Group type: EXPERIMENTAL
Intervention: Dexmedetomidine (0.4 μg/(kg×h))
Number of subjects: 60

Group type: COMPARATOR
Intervention: Saline solution (control)
Number of subjects: 60
Study: 24117597

Group type: EXPERIMENTAL
Intervention: Lixisenatide one-step dose increase
Number of subjects: 484

Group type: EXPERIMENTAL
Intervention: Lixisenatide two-step dose increase
Number of subjects: 484

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 484
Study: 23355162

Group type: EXPERIMENTAL
Intervention: Fibrin glue (n = 50)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Tacks (n = 50)
Number of subjects: 100
Study: 20308907

Group type: COMPARATOR
Intervention: Propofol 200 mg
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Propofol 350 mg
Number of subjects: 20
Study: 18093197

Group type: EXPERIMENTAL
Intervention: Gentamicin-collagen sponge (GC)
Number of subjects: 200

Group type: COMPARATOR
Intervention: Primary closure (PC)
Number of subjects: 200
Study: 16649860

Group type: EXPERIMENTAL
Intervention: Groups of 3, 4, and 5 people
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: 3-person groups
Number of subjects: 0
Study: 12166353

Group type: EXPERIMENTAL
Intervention: Barnidipine
Number of subjects: 59

Group type: COMPARATOR
Intervention: Felodipine
Number of subjects: 59
Study: 9864711

Group type: EXPERIMENTAL
Intervention: Pimozide (1 mg daily for 3-12 months)
Number of subjects: 44

Group type: COMPARATOR
Intervention: Selegiline and Vitamin E (control group)
Number of subjects: 44
Study: 7621648

Group type: EXPERIMENTAL
Intervention: Saline contrast transoesophageal echocardiography with the Valsalva manoeuvre
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: Transoesophageal colour Doppler echocardiography
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: Transthoracic colour Doppler echocardiography
Number of subjects: 28

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 28
Study: 2912000

Group type: EXPERIMENTAL
Intervention: Zinc (Zn) supplementation
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Zinc (Zn) and Iron (Fe) supplementation
Number of subjects: 0
Study: 330168

Group type: EXPERIMENTAL
Intervention: Aprindine
Number of subjects: 98

Group type: COMPARATOR
Intervention: Disopyramide
Number of subjects: 98

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 98
Study: 6958187

Group type: EXPERIMENTAL
Intervention: Behavioural change treatment programme (Section II)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Cardiologist-led treatment programme (Section I)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (regular care from own physician)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Dropout comparison group
Number of subjects: 0
Study: 31128057

Group type: EXPERIMENTAL
Intervention: ICE (ifosfamide, carboplatin, and etoposide)
Number of subjects: 61

Group type: COMPARATOR
Intervention: TC (topotecan/cyclophosphamide)
Number of subjects: 61
Study: 30099285

Group type: EXPERIMENTAL
Intervention: Online mindfulness course (n=107)
Number of subjects: 185

Group type: COMPARATOR
Intervention: Waitlist control (n=78)
Number of subjects: 185
Study: 26329838

Group type: EXPERIMENTAL
Intervention: Sport rock climbing (SRC) exercises for 60 minutes a day, three days a week for 8 weeks
Number of subjects: 19
Study: 24771196

Group type: EXPERIMENTAL
Intervention: Robotic transaxillary cervical (TAC) parathyroidectomy
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Robotic transthoracic mediastinal (TTM) parathyroidectomy
Number of subjects: 14
Study: 21739158

Group type: EXPERIMENTAL
Intervention: Group B: 2/3 of I.V. predicted carboplatin dose by I.V. infusion and the rest 1/3 as aerosol (jet nebulised D1)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Group A: I.V. chemotherapy (carboplatin AUC ≈ 5.5 D1)
Number of subjects: 60
Study: 19298231

Group type: EXPERIMENTAL
Intervention: Lactobacillus F19
Number of subjects: 179

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 179
Study: 17897478

Group type: EXPERIMENTAL
Intervention: Salmeterol plus fluticasone propionate (SFC)
Number of subjects: 66

Group type: COMPARATOR
Intervention: Fluticasone propionate plus montelukast (FP/M)
Number of subjects: 66
Study: 15240584

Group type: EXPERIMENTAL
Intervention: Growth Hormone (GH) treatment (0.074 mg/kg, sc three times per week)
Number of subjects: 68

Group type: COMPARATOR
Intervention: Placebo treatment
Number of subjects: 68
Study: 12191749

Group type: EXPERIMENTAL
Intervention: Continuous Positive Airway Pressure (CPAP) at 7.5 cmH(2)O pressure
Number of subjects: 58

Group type: COMPARATOR
Intervention: Standard oxygen therapy (60% inhaled oxygen)
Number of subjects: 58
Study: 9707845

Group type: EXPERIMENTAL
Intervention: KOH preparation
Number of subjects: 144

Group type: COMPARATOR
Intervention: Gram's stain
Number of subjects: 144

Group type: COMPARATOR
Intervention: LPCB
Number of subjects: 144

Group type: EXPERIMENTAL
Intervention: CFW
Number of subjects: 144

Group type: EXPERIMENTAL
Intervention: KOH preparation and CFW
Number of subjects: 144
Study: 7621489

Group type: EXPERIMENTAL
Intervention: 0.24% NaF/silica abrasive dentifrice containing 0.3% triclosan/2.0% copolymer
Number of subjects: 3462

Group type: COMPARATOR
Intervention: Similar dentifrice without triclosan/copolymer
Number of subjects: 3462
Study: 2239797

Group type: EXPERIMENTAL
Intervention: 465 kcal/d (HE group)
Number of subjects: 542

Group type: COMPARATOR
Intervention: 52 kcal/d (LE group)
Number of subjects: 542
Study: 407963

Group type: EXPERIMENTAL
Intervention: Parenteral nutrition with a high calorie and nitrogen content (group A)
Number of subjects: 15

Group type: COMPARATOR
Intervention: Intravenous dextrose/saline solution (group B)
Number of subjects: 15
Study: 31493054

Group type: EXPERIMENTAL
Intervention: Direct defect closure
Number of subjects: 241

Group type: COMPARATOR
Intervention: No direct defect closure
Number of subjects: 241
Study: 31271193

Group type: EXPERIMENTAL
Intervention: Phenylalanine intake ranging from 7.20 to 40.0 mg .kg‐1 .d‐1
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Adaptation to a milkshake diet providing protein at 1.0 g.kg‐1 .d‐1 and energy at 1.7 × REE for two days prior to study
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Direct amino acid oxidation method measuring oxidation of l‐[1‐13C]phenylalanine to 13CO2
Number of subjects: 12
Study: 28154796

Group type: EXPERIMENTAL
Intervention: Continuous feedback (n=7)
Number of subjects: 14

Group type: COMPARATOR
Intervention: Intermittent feedback (n=7)
Number of subjects: 14
Study: 25993119

Group type: EXPERIMENTAL
Intervention: Anifrolumab (anti-IFNAR1 receptor antibody)
Number of subjects: 0
Study: 24925440

Group type: EXPERIMENTAL
Intervention: Voriconazole (400 mg every 12 h on day 1, then 300 mg every 12 h for 27.5 days)
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Voriconazole
Number of subjects: 36

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 36
Study: 21775147

Group type: EXPERIMENTAL
Intervention: One-stage ACL revision technique using calcium phosphate bone cement
Number of subjects: 10

Group type: COMPARATOR
Intervention: Standard reconstruction with bone-patellar tendon-bone autograft with bioabsorbable interference screw fixation (Control)
Number of subjects: 10
Study: 19317630

Group type: EXPERIMENTAL
Intervention: Escitalopram
Number of subjects: 4301

Group type: COMPARATOR
Intervention: Other antidepressants (citalopram, duloxetine, fluoxetine, paroxetine, sertraline, venlafaxine)
Number of subjects: 4301
Study: 17584698

Group type: EXPERIMENTAL
Intervention: Propranolol for 10 to 12 months
Number of subjects: 46

Group type: COMPARATOR
Intervention: Normal individuals (control group)
Number of subjects: 46
Study: 15201999

Group type: EXPERIMENTAL
Intervention: Interferon-alpha (IFN-alpha)
Number of subjects: 263
Study: 12365828

Group type: EXPERIMENTAL
Intervention: Intra-arterial thrombolysis with recombinant pro-urokinase (r-pro-UK)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Intra-arterial thrombolysis with other agents
Number of subjects: 0
Study: 10214787

Group type: EXPERIMENTAL
Intervention: Percutaneous tracheostomy (PT) under bronchoscopic surveillance
Number of subjects: 130

Group type: COMPARATOR
Intervention: Open tracheostomy (OT)
Number of subjects: 130

Group type: EXPERIMENTAL
Intervention: Cost estimation for PT
Number of subjects: 130
Study: 8545790

Group type: EXPERIMENTAL
Intervention: Group A: Split course radiotherapy (1.8 to 2 Gy single dose) over 10 weeks with chemotherapy (5‐FU, methotrexate, cyclophosphamide)
Number of subjects: 48

Group type: COMPARATOR
Intervention: Group B: Conventional radiotherapy (1.8 to 2 Gy single dose) over 6 weeks with chemotherapy (5‐FU, mitomycin C)
Number of subjects: 48
Study: 2227074

Group type: EXPERIMENTAL
Intervention: Controlled-release theophylline
Number of subjects: 104

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 104
Study: 345993

Group type: EXPERIMENTAL
Intervention: Indomethacin
Number of subjects: 47

Group type: COMPARATOR
Intervention: Aspirin
Number of subjects: 47

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 47
Study: 30878323

Group type: EXPERIMENTAL
Intervention: Dietary intervention (4 tailored educational sessions by a community health worker + text messaging until birth)
Number of subjects: 230

Group type: EXPERIMENTAL
Intervention: Probiotics (daily capsules containing Lactobacillus rhamnosus GG and Bifidobacterium lactis BB12)
Number of subjects: 230

Group type: EXPERIMENTAL
Intervention: Dietary intervention
Number of subjects: 230

Group type: EXPERIMENTAL
Intervention: Probiotics
Number of subjects: 230
Study: 27634419

Group type: EXPERIMENTAL
Intervention: NGF injection in infrapatellar fat pad (IFP) followed by acid infusion (5 mL of phosphate-buffered acidic saline at 20 mL/h)
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: NGF injection in tibialis anterior (TA) muscle followed by acid infusion (10 mL at 30 mL/h)
Number of subjects: 32

Group type: COMPARATOR
Intervention: Isotonic saline injection in infrapatellar fat pad (IFP) followed by acid infusion (5 mL of phosphate-buffered acidic saline at 20 mL/h)
Number of subjects: 32

Group type: COMPARATOR
Intervention: Isotonic saline injection in tibialis anterior (TA) muscle followed by acid infusion (10 mL at 30 mL/h)
Number of subjects: 32
Study: 25843816

Group type: EXPERIMENTAL
Intervention: Submucosal dexamethasone 8 mg
Number of subjects: 40

Group type: COMPARATOR
Intervention: Control (no dexamethasone)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 40
Study: 24716610

Group type: EXPERIMENTAL
Intervention: Intravenous KGF (60 μg/kg) for 3 days
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: In vitro BAL fluid from KGF-treated subjects
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: BAL from KGF-pretreated group
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Inhibition of GM-CSF receptor activation
Number of subjects: 0
Study: 22879574

Group type: EXPERIMENTAL
Intervention: Pain management algorithms coupled with a comprehensive adoption program
Number of subjects: 485

Group type: COMPARATOR
Intervention: Education alone
Number of subjects: 485
Study: 19390327

Group type: EXPERIMENTAL
Intervention: ATV/r (boosted atazanavir)
Number of subjects: 248

Group type: COMPARATOR
Intervention: LPV/r (boosted lopinavir)
Number of subjects: 248
Study: 17703258

Group type: EXPERIMENTAL
Intervention: Mitral insufficiency
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Moderate mitral insufficiency
Number of subjects: 0
Study: 15450725

Group type: EXPERIMENTAL
Intervention: Overall treatment time of radiotherapy reduced to 5.5 weeks, 6.5 weeks, and 9.5 weeks with a total dose of 66-68 Gy, 2 Gy/fx.
Number of subjects: 209
Study: 11520380

Group type: EXPERIMENTAL
Intervention: Comprehensive Health Enhancement Support System (CHESS)
Number of subjects: 246
Study: 9746769

Group type: EXPERIMENTAL
Intervention: D-FISH technique for monitoring therapy in CML
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: D-FISH analysis of interphase nuclei from blood
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: D-FISH analysis
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: D-FISH technique
Number of subjects: 10
Study: 7911136

Group type: EXPERIMENTAL
Intervention: 250-micrograms bolus injection of somatostatin + 250 micrograms/h slow infusion
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: 500-micrograms bolus injection of somatostatin + 250 micrograms/h slow infusion
Number of subjects: 19

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 19
Study: 3295548

Group type: EXPERIMENTAL
Intervention: Laser photocoagulation
Number of subjects: 174

Group type: COMPARATOR
Intervention: Control (therapy without photocoagulation)
Number of subjects: 174
Study: 29405252

Group type: EXPERIMENTAL
Intervention: No supplementation and no blood test on postoperative day 1 (intervention group)
Number of subjects: 146

Group type: COMPARATOR
Intervention: Standard follow-up (measurement of calcium and parathyroid hormone on postoperative day 1 and systematic supplementation with calcium and vitamin D; control group)
Number of subjects: 146

Group type: EXPERIMENTAL
Intervention: Patients with no well perfused parathyroid gland identified by angiography (excluded patients)
Number of subjects: 146
Study: 27271190

Group type: EXPERIMENTAL
Intervention: Intensive lifestyle intervention (ILI)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Large initial weight loss
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Maintenance of weight loss
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Full regain of weight after large initial weight loss
Number of subjects: 0

Group type: COMPARATOR
Intervention: No weight loss
Number of subjects: 0
Study: 24911369

Group type: EXPERIMENTAL
Intervention: Aprepitant regimen (ondansetron and dexamethasone plus aprepitant)
Number of subjects: 848

Group type: COMPARATOR
Intervention: Control (ondansetron and dexamethasone)
Number of subjects: 848
Study: 21987530

Group type: EXPERIMENTAL
Intervention: Pharmacist counseling
Number of subjects: 67

Group type: COMPARATOR
Intervention: Printed materials (Control)
Number of subjects: 67
Study: 20482322

Group type: EXPERIMENTAL
Intervention: Teriparatide (20 microg/day)
Number of subjects: 868

Group type: EXPERIMENTAL
Intervention: Raloxifene (60 mg/day)
Number of subjects: 868

Group type: COMPARATOR
Intervention: No active treatment
Number of subjects: 868
Study: 18572079

Group type: EXPERIMENTAL
Intervention: Bosentan
Number of subjects: 185

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 185
Study: 16097980

Group type: EXPERIMENTAL
Intervention: Modified Misgav-Ladach (MML) technique
Number of subjects: 162

Group type: COMPARATOR
Intervention: Pfannenstiel-Kerr technique
Number of subjects: 162
Study: 12626201

Group type: EXPERIMENTAL
Intervention: Aprotinin (280 mg in pump prime)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 30
Study: 12903826

Group type: EXPERIMENTAL
Intervention: Esmolol (2 mg/kg)
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: Alfentanil (30 microg/kg)
Number of subjects: 35

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 35
Study: 7862470

Group type: EXPERIMENTAL
Intervention: Apple juice (4 ounces)
Number of subjects: 28

Group type: COMPARATOR
Intervention: White grape juice (8 ounces)
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: Both juices
Number of subjects: 28
Study: 8465822

Group type: EXPERIMENTAL
Intervention: Glucose-polymer solution
Number of subjects: 8
Study: 3079994

Group type: EXPERIMENTAL
Intervention: Branched chain‐enriched amino acid solutions (valine-enriched)
Number of subjects: 37

Group type: EXPERIMENTAL
Intervention: Branched chain‐enriched amino acid solutions (leucine-enriched)
Number of subjects: 37

Group type: COMPARATOR
Intervention: Standard amino acid solution
Number of subjects: 37
Study: 30336598

Group type: EXPERIMENTAL
Intervention: Iron Treatment Group (ITG) - 325mg/d of ferrous sulphate for 11 weeks
Number of subjects: 22

Group type: COMPARATOR
Intervention: Control Group (CG)
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: Iron Treatment Group (ITG)
Number of subjects: 22
Study: 27352777

Group type: EXPERIMENTAL
Intervention: Milk with guar gum (2.5g)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Milk with alginate (2.5g)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Milk with carrageenan (2.5g)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Milk (2% M.F.) - Control
Number of subjects: 30
Study: 27132446

Group type: EXPERIMENTAL
Intervention: Auscultation
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Partial pressure of carbon dioxide in end-expiration (P(ET)CO2)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Transillumination technique
Number of subjects: 60
Study: 23528388

Group type: EXPERIMENTAL
Intervention: Mirror therapy (5 days/week, 2 sessions/day for 21 days, 15 min/session)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Conventional rehabilitation program without mirror therapy
Number of subjects: 60
Study: 21627403

Group type: EXPERIMENTAL
Intervention: High-dose parenteral polyoestradiol phosphate (PEP) 240 mg i.m. twice a month for 2 months and thereafter monthly
Number of subjects: 915

Group type: COMPARATOR
Intervention: Combined androgen deprivation (CAD) with flutamide (Eulexin®) 250 mg per os three times daily and triptorelin (Decapeptyl®) 3.75 mg i.m. per month or bilateral orchidectomy
Number of subjects: 915
Study: 18757238

Group type: EXPERIMENTAL
Intervention: 25 mg aspirin (ASA) and 200 mg extended-release dipyridamole (ER-DP) twice a day
Number of subjects: 20332

Group type: EXPERIMENTAL
Intervention: 75 mg clopidogrel once a day
Number of subjects: 20332

Group type: EXPERIMENTAL
Intervention: 80 mg telmisartan once per day
Number of subjects: 20332

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20332
Study: 16825509

Group type: EXPERIMENTAL
Intervention: 16S rDNA polymerase chain reaction (PCR) assay
Number of subjects: 1233

Group type: COMPARATOR
Intervention: Blood culturing
Number of subjects: 1233
Study: 12908135

Group type: EXPERIMENTAL
Intervention: Concurrent chemoradiation strategies
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Sequential therapy
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Platinum and 5-fluorouracil drug combinations
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Taxane-based regimens
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: New biologic agents in combined modality treatment schemes
Number of subjects: 0
Study: 11127445

Group type: EXPERIMENTAL
Intervention: Standard dose of enalapril (mean dose achieved 17.9 mg/day)
Number of subjects: 248

Group type: EXPERIMENTAL
Intervention: High dose of enalapril (mean dose achieved 42 mg/day)
Number of subjects: 248
Study: 7746415

Group type: EXPERIMENTAL
Intervention: linopirdine
Number of subjects: 35
Study: 2154428

Group type: EXPERIMENTAL
Intervention: Azithromycin (three regimens including a single oral dose)
Number of subjects: 168

Group type: COMPARATOR
Intervention: Doxycycline (standard treatment)
Number of subjects: 168

Group type: EXPERIMENTAL
Intervention: Azithromycin
Number of subjects: 168
Study: 7470437

Group type: EXPERIMENTAL
Intervention: 13% protein-energy in three meals/d for the first week
Number of subjects: 38

Group type: EXPERIMENTAL
Intervention: 15% protein-energy as three meals/d
Number of subjects: 38

Group type: EXPERIMENTAL
Intervention: 13% protein-energy as five or one meal/d
Number of subjects: 38

Group type: EXPERIMENTAL
Intervention: 15% protein-energy as five meals/d or 10% protein-energy as one meal/d
Number of subjects: 38

Group type: COMPARATOR
Intervention: Isoenergetic diet with lower-protein concentration fed as fewer meals
Number of subjects: 38
Study: 31875053

Group type: EXPERIMENTAL
Intervention: LAV% of larger bullae
Number of subjects: 99

Group type: EXPERIMENTAL
Intervention: Two ED % of scales and location-dependent variables
Number of subjects: 99
Study: 28008750

Group type: EXPERIMENTAL
Intervention: Probiotic mix (Lactobacillus acidophilus and casei; Lactococcus lactis; Bifidobacterium bifidum and lactis; 2 × 10^10 colony‐forming units/day)
Number of subjects: 43

Group type: EXPERIMENTAL
Intervention: Probiotic mix
Number of subjects: 43
Study: 26218852

Group type: EXPERIMENTAL
Intervention: Cortisol (20 mg, single oral dose)
Number of subjects: 29

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 29
Study: 23727103

Group type: EXPERIMENTAL
Intervention: Midazolam (Mi) + Morphine (Mo)
Number of subjects: 1763

Group type: COMPARATOR
Intervention: Morphine (Mo) alone
Number of subjects: 1763